BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 14, 2010
View Archived Issues
Vardenafil improves exercise capacity in phase III trial in subjects with PAH
Read More
New dual mTOR/PI3K-alpha inhibitor PF-04979064 may advance to clinic as anticancer agent
Read More
MEDI-578 has analgesic effects in rat model of inflammatory pain
Read More
New partial 5-HT3 receptor agonist described for treatment of IBS
Read More
Omecamtiv mecarbil improves left atrial contractility in healthy males
Read More
Vaxin and Stabilitech to collaborate in developing anthrax vaccine
Read More
Targacept describes new nicotinic acetylcholine receptor modulators
Read More
Shire reports highlights of second quarter 2010
Read More
Clinical data on sevuparin in healthy adults support evaluation in phase II trial in malaria
Read More
Santarus acquires rights to Rhucin and VLA-1-targeted antibody
Read More
Tekmira Pharma offers program update
Read More
Addex receives grant to support phase II trial of ADX-48621 for Parkinson's dyskinesia
Read More
AP-214 reduces development of acute kidney injury in phase II trial
Read More
FDA clarifies position on ProAmatine
Read More
Ono Pharma and Astellas submit minodronic acid MAA in Japan for osteoporosis
Read More
Advinus Therapeutics discovers new molecule for diabetes type 2
Read More
Genzyme to sell genetic testing business to LabCorp
Read More
Argenta and Genentech expand collaboration to include BioFocus
Read More
Cyclacel and FDA agree on a special protocol assessment for phase III sapacitabine trial
Read More
Forest Laboratories responds to FDA's complete response letter on roflumilast
Read More
XenoPort advances arbaclofen placarbil to phase III for spasticity in MS
Read More
Seattle Genetics discontinues lintuzumab development program
Read More
Merck & Co. identifies new muscarinic acetylcholine M1 receptor modulators
Read More
New CRFR-1 antagonists claimed by Emory University
Read More
Enanta Pharmaceuticals discloses novel inhibitors of HCV NS5
Read More
Ariad begins phase II trial of ponatinib in chronic myeloid leukemia
Read More